Workflow
Novartis(NVS)
icon
Search documents
Novartis: Explaining YE24 Loss Of Momentum, Outlining Prospects For 2025
Seeking Alpha· 2025-01-10 21:32
If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio, or simply access the investment bank-grade financial models and research. I hope to see you there.The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecast ...
NVS vs. LLY: Which Stock Should Value Investors Buy Now?
ZACKS· 2024-12-17 17:41
Investors with an interest in Large Cap Pharmaceuticals stocks have likely encountered both Novartis (NVS) and Eli Lilly (LLY) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Styl ...
Are Investors Undervaluing Novartis (NVS) Right Now?
ZACKS· 2024-12-17 15:40
While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use tri ...
Novartis: Time To Increase
Seeking Alpha· 2024-12-13 12:28
Since our last update ( Q2 results - Fig 1), Novartis (NYSE: NVS ) ( OTCPK:NVSEF ) reported its Q3 financials and also provided a Capital Market Update at the end of November. At the Lab in April 2024, supportedBuy-side hedge professionals conducting fundamental, income oriented, long term analysis across sectors globally in developed markets. Please shoot us a message or leave a comment to discuss ideas.DISCLOSURE: All of our articles are a matter of opinion, informed as they might be, and must be treated ...
New Phase IIIB data shows Novartis Fabhalta® improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy
GlobeNewswire News Room· 2024-12-06 06:15
In the Phase IIIB APPULSE-PNH study, oral Fabhalta® (iptacopan) improved the average hemoglobin (Hb) level versus baseline in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who were switched from anti-C5 therapies (Hb ≥10g/dL following treatment with eculizumab or ravulizumab)1,2PNH is a rare, chronic and serious complement-mediated blood disorder, characterized by hemolysis, anemia, thrombosis and other symptoms, and patients are often treated with anti-C5 therapies3-5Findings from APPULSE-P ...
Why Novartis (NVS) is a Top Growth Stock for the Long-Term
ZACKS· 2024-12-04 15:51
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.It also includes access to the Zacks Style Scores. What a ...
Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion
ZACKS· 2024-12-03 19:40
Novartis (NVS) has entered into a global license and collaboration agreement with PTC Therapeutics (PTCT) for the latter’s Huntington's disease candidate to strengthen NVS’ neuroscience pipeline.NVS also announced a collaboration with Olema Pharmaceuticals, Inc. (OLMA) for a breast cancer drug.Year to date, shares of Novartis have risen 3.8% compared with the industry’s growth of 8.9%.Image Source: Zacks Investment ResearchNVS’ Licensing Deal With PTCTNovartis will in-license PTC Therapeutics’ PTC518.  The ...
Olema: Cash Infusion And Supply Agreement With Novartis Carries The Tide Forward
Seeking Alpha· 2024-12-02 21:27
This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...
EC Approves NVS' Kisqali for a Broad Population in Early Breast Cancer
ZACKS· 2024-11-28 18:05
Novartis (NVS) announced that the European Commission (“EC”) has approved its breast cancer drug Kisqali (ribociclib) for a broad population.The EC has approved Kisqali in combination with an aromatase inhibitor (AI) for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (EBC) at high risk of recurrence.Kisqali is a selective cyclin-dependent kinase inhibitor, a class of drugs that helps slow the progression of ...
Novartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence
GlobeNewswire News Room· 2024-11-27 06:15
Approval is based on Phase III NATALEE data showing Kisqali® (ribociclib) plus adjuvant endocrine therapy (ET) demonstrated clinically meaningful invasive disease-free survival (iDFS) benefit in patients with stage II or III HR+/HER2- early breast cancer (EBC), consistent across all subgroups1,2With this broad indication, nearly twice as many EBC patients in Europe, including those with node-negative disease, could now be eligible for treatment with Kisqali to help reduce their risk of recurrence3Despite ET ...